CO6382112A2 - Pirrolidinas - Google Patents

Pirrolidinas

Info

Publication number
CO6382112A2
CO6382112A2 CO11058068A CO11058068A CO6382112A2 CO 6382112 A2 CO6382112 A2 CO 6382112A2 CO 11058068 A CO11058068 A CO 11058068A CO 11058068 A CO11058068 A CO 11058068A CO 6382112 A2 CO6382112 A2 CO 6382112A2
Authority
CO
Colombia
Prior art keywords
compounds
formula
preparation
pelvic pain
chronic pelvic
Prior art date
Application number
CO11058068A
Other languages
English (en)
Inventor
Kevin Neil Dack
James Edward John Mills
Sarah Skerratt
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of CO6382112A2 publication Critical patent/CO6382112A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La invención se refiere a una clase de compuestos de pirrolidina de fórmula (1), y sus derivados farmacéuticamente aceptables, a su uso en medicina, a composiciones que los contienen, y a procesos para su preparación. También se refiere a intermedios utilizados en la preparación de dichos compuestos y derivados. En particular, los compuestos de fórmula (I) son útiles para el tratamiento de trastornos mediados por EP2, como la endometriosis, los fibroides uterinos (leiomiomata), la menorragia, la adenomiosis, la dismenorrea primaria y secundaria (incluyendo los síntomas de dispareunia, disquexia y dolor pélvico crónico), el síndrome del dolor pélvico crónico, la enfermedad del riñón poliquístico y el síndrome del ovario poliquístico.
CO11058068A 2008-11-10 2011-05-11 Pirrolidinas CO6382112A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11286908P 2008-11-10 2008-11-10

Publications (1)

Publication Number Publication Date
CO6382112A2 true CO6382112A2 (es) 2012-02-15

Family

ID=41503565

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11058068A CO6382112A2 (es) 2008-11-10 2011-05-11 Pirrolidinas

Country Status (31)

Country Link
US (1) US8278343B2 (es)
EP (1) EP2364296A1 (es)
JP (1) JP2012508225A (es)
KR (1) KR20110083733A (es)
CN (1) CN102209710A (es)
AP (1) AP2011005728A0 (es)
AR (1) AR074314A1 (es)
AU (1) AU2009312427B2 (es)
BR (1) BRPI0920924A2 (es)
CA (1) CA2741589A1 (es)
CL (1) CL2011001034A1 (es)
CO (1) CO6382112A2 (es)
CR (1) CR20110217A (es)
CU (1) CU20110093A7 (es)
DO (1) DOP2011000127A (es)
EA (1) EA201100549A1 (es)
EC (1) ECSP11011032A (es)
GE (1) GEP20125607B (es)
IL (1) IL212490A0 (es)
MA (1) MA32782B1 (es)
MX (1) MX2011004903A (es)
NI (1) NI201100092A (es)
NZ (1) NZ592311A (es)
PA (1) PA8848001A1 (es)
PE (1) PE20110663A1 (es)
SV (1) SV2011003896A (es)
TN (1) TN2011000211A1 (es)
TW (1) TW201022234A (es)
UY (1) UY32228A (es)
WO (1) WO2010052625A1 (es)
ZA (1) ZA201104310B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR074776A1 (es) * 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
TW201326154A (zh) 2011-11-28 2013-07-01 拜耳知識產權公司 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑
JPWO2013176220A1 (ja) * 2012-05-25 2016-01-14 国立大学法人京都大学 概日リズム調整
CN110041269A (zh) * 2019-05-16 2019-07-23 海门瑞一医药科技有限公司 一种2-氯-5-羟基嘧啶的制备方法
EP4359399A1 (en) * 2021-06-24 2024-05-01 Reservoir Neuroscience, Inc. Ep2 antagonist compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU646722B2 (en) * 1991-01-21 1994-03-03 Shionogi Seiyaku Kabushiki Kaisha 3-benzylidene-1-carbamoyl-2-pyrrolidone analog
US7335680B2 (en) * 2001-12-20 2008-02-26 Laboratoires Serono Sa Pyrrolidine derivatives as prostaglandin modulators
WO2007005176A1 (en) * 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7550448B2 (en) * 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
DE102006039912A1 (de) * 2006-08-25 2008-03-20 Bayer Healthcare Ag Substituierte Spirotetronsäuren und ihre Verwendung
CA2686517A1 (en) * 2007-05-10 2008-11-20 Pfizer Limited Azetidine derivatives and their use as prostaglandin e2 antagonists

Also Published As

Publication number Publication date
IL212490A0 (en) 2011-06-30
MA32782B1 (fr) 2011-11-01
DOP2011000127A (es) 2011-07-15
CL2011001034A1 (es) 2011-11-11
AU2009312427A1 (en) 2010-05-14
ZA201104310B (en) 2012-02-29
CU20110093A7 (es) 2012-01-31
MX2011004903A (es) 2011-05-30
TW201022234A (en) 2010-06-16
BRPI0920924A2 (pt) 2016-10-04
US20100120793A1 (en) 2010-05-13
AR074314A1 (es) 2011-01-05
AP2011005728A0 (en) 2011-06-30
EP2364296A1 (en) 2011-09-14
AU2009312427B2 (en) 2011-10-20
NZ592311A (en) 2012-12-21
UY32228A (es) 2010-06-30
JP2012508225A (ja) 2012-04-05
WO2010052625A1 (en) 2010-05-14
US8278343B2 (en) 2012-10-02
CA2741589A1 (en) 2010-05-14
TN2011000211A1 (fr) 2012-12-17
EA201100549A1 (ru) 2011-12-30
CR20110217A (es) 2011-05-12
KR20110083733A (ko) 2011-07-20
ECSP11011032A (es) 2011-06-30
GEP20125607B (en) 2012-08-10
SV2011003896A (es) 2011-07-05
NI201100092A (es) 2011-10-31
PA8848001A1 (es) 2010-06-28
PE20110663A1 (es) 2011-09-23
CN102209710A (zh) 2011-10-05

Similar Documents

Publication Publication Date Title
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
DOP2021000183A (es) Compuestos tricíclicos condensados útiles como agentes anticancerígenos
PA8827901A1 (es) Derivados de quinoxalin- y quinolin-carboxamida
CO6382112A2 (es) Pirrolidinas
CY1119661T1 (el) 17-υδροξυ-17-πενταφθοροαιθυλο-οιστρα-4,9(10)-διεν-11-αρυλο-παραγωγα, μεθοδοι για την παραγωγη αυτων και χρηση αυτων για την αγωγη παθησεων
CU20090180A7 (es) Derivados de piridina
CL2018001325A1 (es) Derivados de indol n-sustituidos como moduladores del receptor de pge2
UY29904A1 (es) Compuestos útiles en terapia
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
PA8623101A1 (es) Compuestos farmaceuticamente activos
CL2009000368A1 (es) 3-(amido o sulfamido)-4-(4-azinil sustituido) benzamidas o benzosulfonamidas; la composicion farmaceutica que los contiene; el uso de los compuestos; y un kit que contiene dichos compeustos; utiles como inhibidores del receptor de quimioquinas cxcr3.
CR11101A (es) Azetidinas
UY30399A1 (es) Uso de antagonistas de cgrp (a), sus enantinmeros, diasternmeros, mezclas y sales farmaccuticamente aceptables para preparar medicamentos, y composiciones que los contienen"
ECSP10010606A (es) Derivados de quinuclidina como antagonistas de receptores muscarinicos m3
CL2019001991A1 (es) Moduladores del receptor de estrógeno.
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения
AR071721A1 (es) Derivados de piridil-prolinamida, composiciones farmaceuticas que los contienen y su uso para el tratamiento de ansiedad, depresion y trastornos del sueno.
CO2024002844A2 (es) Compuestos espirocíclicos
CR9595A (es) Derivados de benzofurarona como moduladores no esteroides de receptores de progesterona
CO6690116A1 (es) Nueva asociación entre la 4-[3-(cis-hexahidrociclopenta[c]pirrol -2(1h)-il]propoxi]benzamida y un antagonista de los receptores nmda y las composiciones famacéuticas que las contienen
ATE525360T1 (de) Neuartige imidazolinylmethyl-aryl-sulfonamide
CO2017012260A2 (es) Derivados de etinilo
CO6331339A2 (es) Derivados de quinuclidina como antagonistas del receptor muscarinico m3
CU20100217A7 (es) Derivados de quinuclidina como antagonistas de receptores muscarínicos m3

Legal Events

Date Code Title Description
FG Application granted
FD Application lapsed